Osteopontin expression correlates with invasiveness in cervical cancer

Jae Yun Song, Jae Kwan Lee, Nak Woo Lee, Bom Woo Yeom, Sun Haeng Kim, Kyu Wan Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: Osteopontin is a secreted, integrin-binding glycophosphoprotein that is overexpressed in many types of cancers and appears to be involved in carcinogenesis and cancer progression. To understand the role of osteopontin in carcinogenesis of cervical cancer, this study was designed to determine whether osteopontin is expressed in cervical cancer and carcinoma in situ (CIS) tissue as well as in normal cervical tissue. Methods: The expression of osteopontin was immunohistochemically analysed from 68 normal cervix, 55 CIS and 52 invasive cervical cancer tissues using a paraffin-embedded tissue array. Immunostaining was evaluated by intensity and the percentage of stained cells. Results: Osteopontin expression in normal, CIS and cervical cancer tissues was two of 68 (2.9%), 43 of 55 (78.2%) and 46 of 52 (88.4%), respectively (P < 0.01). High intensity (strong positive)/high proportion (more than 50%) staining seen in CIS and cervical cancer tissue samples was 45 of 55 (81.8%)/22 of 55 (40.0%) and 50 of 52 (96.2%)/31 of 52 (59.7%), respectively (P = 0.029 and P = 0.054). There was no significant correlation between the immunostaining score and stage and the immunostaining score and survival. Conclusion: Osteopontin may have a potential use as a diagnostic factor for cervical cancer and osteopontin expression is closely correlated with carcinogenesis and invasion of cervical cancer.

Original languageEnglish
Pages (from-to)434-438
Number of pages5
JournalAustralian and New Zealand Journal of Obstetrics and Gynaecology
Volume49
Issue number4
DOIs
Publication statusPublished - 2009 Aug 1

Fingerprint

Osteopontin
Uterine Cervical Neoplasms
Carcinoma in Situ
Carcinogenesis
Integrins
Cervix Uteri
Paraffin
Neoplasms
Staining and Labeling

Keywords

  • Immunohistochemistry
  • Neoplastic cell transformation
  • Osteopontin
  • Tissue array analysis
  • Uterine cervical neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Osteopontin expression correlates with invasiveness in cervical cancer. / Song, Jae Yun; Lee, Jae Kwan; Lee, Nak Woo; Yeom, Bom Woo; Kim, Sun Haeng; Lee, Kyu Wan.

In: Australian and New Zealand Journal of Obstetrics and Gynaecology, Vol. 49, No. 4, 01.08.2009, p. 434-438.

Research output: Contribution to journalArticle

@article{224cf2f7b0e74d69a69fec0a1f224eaa,
title = "Osteopontin expression correlates with invasiveness in cervical cancer",
abstract = "Aim: Osteopontin is a secreted, integrin-binding glycophosphoprotein that is overexpressed in many types of cancers and appears to be involved in carcinogenesis and cancer progression. To understand the role of osteopontin in carcinogenesis of cervical cancer, this study was designed to determine whether osteopontin is expressed in cervical cancer and carcinoma in situ (CIS) tissue as well as in normal cervical tissue. Methods: The expression of osteopontin was immunohistochemically analysed from 68 normal cervix, 55 CIS and 52 invasive cervical cancer tissues using a paraffin-embedded tissue array. Immunostaining was evaluated by intensity and the percentage of stained cells. Results: Osteopontin expression in normal, CIS and cervical cancer tissues was two of 68 (2.9{\%}), 43 of 55 (78.2{\%}) and 46 of 52 (88.4{\%}), respectively (P < 0.01). High intensity (strong positive)/high proportion (more than 50{\%}) staining seen in CIS and cervical cancer tissue samples was 45 of 55 (81.8{\%})/22 of 55 (40.0{\%}) and 50 of 52 (96.2{\%})/31 of 52 (59.7{\%}), respectively (P = 0.029 and P = 0.054). There was no significant correlation between the immunostaining score and stage and the immunostaining score and survival. Conclusion: Osteopontin may have a potential use as a diagnostic factor for cervical cancer and osteopontin expression is closely correlated with carcinogenesis and invasion of cervical cancer.",
keywords = "Immunohistochemistry, Neoplastic cell transformation, Osteopontin, Tissue array analysis, Uterine cervical neoplasms",
author = "Song, {Jae Yun} and Lee, {Jae Kwan} and Lee, {Nak Woo} and Yeom, {Bom Woo} and Kim, {Sun Haeng} and Lee, {Kyu Wan}",
year = "2009",
month = "8",
day = "1",
doi = "10.1111/j.1479-828X.2009.01027.x",
language = "English",
volume = "49",
pages = "434--438",
journal = "Australian and New Zealand Journal of Obstetrics and Gynaecology",
issn = "0004-8666",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Osteopontin expression correlates with invasiveness in cervical cancer

AU - Song, Jae Yun

AU - Lee, Jae Kwan

AU - Lee, Nak Woo

AU - Yeom, Bom Woo

AU - Kim, Sun Haeng

AU - Lee, Kyu Wan

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Aim: Osteopontin is a secreted, integrin-binding glycophosphoprotein that is overexpressed in many types of cancers and appears to be involved in carcinogenesis and cancer progression. To understand the role of osteopontin in carcinogenesis of cervical cancer, this study was designed to determine whether osteopontin is expressed in cervical cancer and carcinoma in situ (CIS) tissue as well as in normal cervical tissue. Methods: The expression of osteopontin was immunohistochemically analysed from 68 normal cervix, 55 CIS and 52 invasive cervical cancer tissues using a paraffin-embedded tissue array. Immunostaining was evaluated by intensity and the percentage of stained cells. Results: Osteopontin expression in normal, CIS and cervical cancer tissues was two of 68 (2.9%), 43 of 55 (78.2%) and 46 of 52 (88.4%), respectively (P < 0.01). High intensity (strong positive)/high proportion (more than 50%) staining seen in CIS and cervical cancer tissue samples was 45 of 55 (81.8%)/22 of 55 (40.0%) and 50 of 52 (96.2%)/31 of 52 (59.7%), respectively (P = 0.029 and P = 0.054). There was no significant correlation between the immunostaining score and stage and the immunostaining score and survival. Conclusion: Osteopontin may have a potential use as a diagnostic factor for cervical cancer and osteopontin expression is closely correlated with carcinogenesis and invasion of cervical cancer.

AB - Aim: Osteopontin is a secreted, integrin-binding glycophosphoprotein that is overexpressed in many types of cancers and appears to be involved in carcinogenesis and cancer progression. To understand the role of osteopontin in carcinogenesis of cervical cancer, this study was designed to determine whether osteopontin is expressed in cervical cancer and carcinoma in situ (CIS) tissue as well as in normal cervical tissue. Methods: The expression of osteopontin was immunohistochemically analysed from 68 normal cervix, 55 CIS and 52 invasive cervical cancer tissues using a paraffin-embedded tissue array. Immunostaining was evaluated by intensity and the percentage of stained cells. Results: Osteopontin expression in normal, CIS and cervical cancer tissues was two of 68 (2.9%), 43 of 55 (78.2%) and 46 of 52 (88.4%), respectively (P < 0.01). High intensity (strong positive)/high proportion (more than 50%) staining seen in CIS and cervical cancer tissue samples was 45 of 55 (81.8%)/22 of 55 (40.0%) and 50 of 52 (96.2%)/31 of 52 (59.7%), respectively (P = 0.029 and P = 0.054). There was no significant correlation between the immunostaining score and stage and the immunostaining score and survival. Conclusion: Osteopontin may have a potential use as a diagnostic factor for cervical cancer and osteopontin expression is closely correlated with carcinogenesis and invasion of cervical cancer.

KW - Immunohistochemistry

KW - Neoplastic cell transformation

KW - Osteopontin

KW - Tissue array analysis

KW - Uterine cervical neoplasms

UR - http://www.scopus.com/inward/record.url?scp=70350192257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350192257&partnerID=8YFLogxK

U2 - 10.1111/j.1479-828X.2009.01027.x

DO - 10.1111/j.1479-828X.2009.01027.x

M3 - Article

VL - 49

SP - 434

EP - 438

JO - Australian and New Zealand Journal of Obstetrics and Gynaecology

JF - Australian and New Zealand Journal of Obstetrics and Gynaecology

SN - 0004-8666

IS - 4

ER -